Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses

Monji, Mikio; Nakatsura, Tetsuya; Senju, Satoru; Yamada, Yoshitake; Sawatsubashi, Motohiro; Shinohara, Masanori; Kageshita, Toshiro; Ono, Tomomichi; Inokuchi, Akira; Nishimura, Yasuharu

doi:10.1158/1078-0432.ccr-04-0475

Cited by 39 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of KM-HN-1 was exceptionally high in the testis (Figure 2A). The high expression levels of KM-HN-1 in the testis were consistent with previous Northern blot data from initial cloning report of KM-HN-1 (Monji et al, 2004). Due to the high proliferation activity in the testis, the high level of KM-HN-1 in testis suggests that it may play a crucial role in cell proliferation.…”

Section: Expression Of Km-hn-1 Mrna In Normal Tissues and Colon Cancerssupporting

confidence: 89%

“…Although KM-HN-1 has previously been identified as a cancer/testis antigen, the study of KM-HN-1 has mainly been limited to mRNA expression level analyses using several cancer tissues and cell lines (Monji et al, 2004;Condomines et al, 2007). KM-HN-1 has been shown to localize to the nucleus in interphase cells and chromosomes in mitotic cells, but the characterization of this protein at the protein level has not been addressed yet.…”

Section: Discussionmentioning

confidence: 99%

“…The clones initially obtained evidenced centrosomal localization and colocalization with hCdc14A in the centrosome. However Monji et al (2004) previously reported that KM-HN-1 is a nuclear protein which evidences colocalization with chromatin. In this study, we found that KM-HN-1 localize to centrosomes as well as nucleus.…”

Section: Introductionmentioning

confidence: 89%

“…From the RT-PCR analysis of cancer tissues and cancer cell lines, the mRNA expression level of KM-HN-1 was shown to be increased in a variety of cancer types, including tongue cancer, melanoma, hepatocellullar carcinoma (Monji et al, 2004;Condomines et al, 2007). We have obtained a KM-HN-1 clone from a yeast two-hybrid screening, using hCdc14A as bait.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The centrosomal localization of KM-HN-1 (MGC33607) depends on the leucine zipper motif and the C-terminal coiled-coil domain

Park

Seo²,

Kim³

et al. 2007

Exp Mol Med

View full text Add to dashboard Cite

Section: Expression Of Km-hn-1 Mrna In Normal Tissues and Colon Cancerssupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The centrosomal localization of KM-HN-1 (MGC33607) depends on the leucine zipper motif and the C-terminal coiled-coil domain

Park

Seo²,

Kim³

et al. 2007

Exp Mol Med

View full text Add to dashboard Cite

“…19) updated with three recently reported CT genes, i.e., CT45 (22), SLLP1/ SPACA3 (20), and KM-HN-1 (21). Of 93 CT genes belonging to 47 families, 64 could be interrogated by 104 probe sets with the Affymetrix HG-U133A or GNFH1 arrays.…”

Section: Expression Of Known Ct Genes In Patients With MM Patients Wmentioning

confidence: 99%

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis

Condomines

Hose

Raynaud

et al. 2007

The Journal of Immunology

109

View full text Add to dashboard Cite

Cancer-testis (CT) Ags are expressed in testis and malignant tumors but rarely in nongametogenic tissues. Due to this pattern, they represent attractive targets for cancer vaccination approaches. The aims of the present study are: 1) to assess the expression of CT genes on a pangenomic base in multiple myeloma (MM); 2) to assess the prognosis value of CT gene expression; and 3) to provide selection strategies for CT Ags in clinical vaccination trials. We report the expression pattern of CT genes in purified MM cells (MMC) of 64 patients with newly diagnosed MM and12 patients with monoclonal gammopathy of unknown significance, in normal plasma cell and B cell samples, and in 20 MMC lines. Of the 46 CT genes interrogated by the Affymetrix HG-U133 set arrays, 35 are expressed in the MMC of at least one patient. Of these, 25 are located on chromosome X. The expression of six CT genes is associated with a shorter event-free survival. The MMC of 98% of the patients express at least one CT gene, 86% at least two, and 70% at least three CT genes. By using a set of 10 CT genes including KM-HN-1, MAGE-C1, MAGE-A3/6/12, MAGE-A5, MORC, DDX43, SPACA3, SSX-4, GAGE-1–8, and MAGE-C2, a combination of at least three CT genes—desirable for circumventing tumor escape mechanisms—is obtained in the MMC of 67% of the patients. Provided that the immunogenicity of the products of these 10 CT genes is confirmed, gene expression profiling could be useful in identifying which CT Ags could be used to vaccinate a given patient.

show abstract

Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression

Wen

Tosun

et al. 2022

JAMA Psychiatry

View full text Add to dashboard Cite

IMPORTANCE Late-life depression (LLD) is characterized by considerable heterogeneity in clinical manifestation. Unraveling such heterogeneity might aid in elucidating etiological mechanisms and support precision and individualized medicine.OBJECTIVE To cross-sectionally and longitudinally delineate disease-related heterogeneity in LLD associated with neuroanatomy, cognitive functioning, clinical symptoms, and genetic profiles. DESIGN, SETTING, AND PARTICIPANTSThe Imaging-Based Coordinate System for Aging and Neurodegenerative Diseases (iSTAGING) study is an international multicenter consortium investigating brain aging in pooled and harmonized data from 13 studies with more than 35 000 participants, including a subset of individuals with major depressive disorder. Multimodal data from a multicenter sample (N = 996), including neuroimaging, neurocognitive assessments, and genetics, were analyzed in this study. A semisupervised clustering method (heterogeneity through discriminative analysis) was applied to regional gray matter (GM) brain volumes to derive dimensional representations. Data were collected from July 2017 to July 2020 and analyzed from July 2020 to December 2021.MAIN OUTCOMES AND MEASURES Two dimensions were identified to delineate LLD-associated heterogeneity in voxelwise GM maps, white matter (WM) fractional anisotropy, neurocognitive functioning, clinical phenotype, and genetics.RESULTS A total of 501 participants with LLD (mean [SD] age, 67.39 [5.56] years; 332 women) and 495 healthy control individuals (mean [SD] age, 66.53 [5.16] years; 333 women) were included. Patients in dimension 1 demonstrated relatively preserved brain anatomy without WM disruptions relative to healthy control individuals. In contrast, patients in dimension 2 showed widespread brain atrophy and WM integrity disruptions, along with cognitive impairment and higher depression severity. Moreover, 1 de novo independent genetic variant (rs13120336; chromosome: 4, 186387714; minor allele, G) was significantly associated with dimension 1 (odds ratio, 2.35; SE, 0.15; P = 3.14 ×10 8 ) but not with dimension 2. The 2 dimensions demonstrated significant single-nucleotide variant-based heritability of 18% to 27% within the general population (N = 12 518 in UK Biobank). In a subset of individuals having longitudinal measurements, those in dimension 2 experienced a more rapid longitudinal change in GM and brain age (Cohen f 2 = 0.03; P = .02) and were more likely to progress to Alzheimer disease (Cohen f 2 = 0.03; P = .03) compared with those in dimension 1 (N = 1431 participants and 7224 scans from the Alzheimer's Disease Neuroimaging Initiative [ADNI], Baltimore Longitudinal Study of Aging [BLSA], and Biomarkers for Older Controls at Risk for Dementia [BIOCARD] data sets).CONCLUSIONS AND RELEVANCE This study characterized heterogeneity in LLD into 2 dimensions with distinct neuroanatomical, cognitive, clinical, and genetic profiles. This dimensional approach provides a potential mechanism for investigating the heterogeneity of LLD and ...

show abstract

Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses

Cited by 39 publications

References 41 publications

The centrosomal localization of KM-HN-1 (MGC33607) depends on the leucine zipper motif and the C-terminal coiled-coil domain

The centrosomal localization of KM-HN-1 (MGC33607) depends on the leucine zipper motif and the C-terminal coiled-coil domain

Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis

Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression

Contact Info

Product

Resources

About